Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays-Reference-Cited by-同舟云学术

Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays

Published:2023-10-16 Issue:5 Volume:2 Page:238-244
ISSN:
Container-title:Exploration of Neuroscience
language:en
Short-container-title:Explor Neurosci

Author:

Yuri Tatsushi¹,Degrieck Rosina²,Minczakiewicz Dagmara²^ORCID,Sato Hideo³,Kamada Jo⁴,Nakazawa Takuya⁴,Vandenbroucke Ina²,Aoyagi Katsumi⁵^ORCID,Nojima Hisashi⁴^ORCID

Affiliation:

1. Product Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, Japan; Product Development Department, Fujirebio Europe N.V., 9052 Gent, Belgium

2. Product Development Department, Fujirebio Europe N.V., 9052 Gent, Belgium

3. Fundamental Research Department, Assay Technology Research Section, Fujirebio Inc., Tokyo 107-0052, Japan

4. Product Development Department, Product Designing 1st section, Fujirebio Inc., Tokyo 107-0052, Japan

5. Research and Development Division, Fujirebio Inc., Tokyo 107-0052, Japan

Abstract

Aim: Apolipoprotein E (ApoE) isoforms, especially the ApoE4 isoform, are genetic risk factors for Alzheimer’s disease (AD). Moreover, the APOE ε4 haplotype has a dose-dependent association with an increased risk of amyloid-related imaging abnormalities (ARIA) in individuals receiving disease-modifying therapy for AD. Therefore, the importance of APOE genotyping or proteotyping has been highlighted. Here, the authors developed fully automated chemiluminescence enzyme-immunoassay kit for ApoE4 and Pan-ApoE, and evaluated their diagnostic concordance with the APOE genotyping. Methods: One hundred seventy-eight specimens were analyzed using the Lumipulse® G ApoE4 and Pan-ApoE for the ApoE proteotype and evaluated its diagnostic concordance with the APOE genotype. Results: The ApoE4 kit specifically detected the ApoE4 concentration in plasma samples, and the polymorphism could be classified clearly by the ratio of ApoE4 and Pan-ApoE amount in plasma. Conclusions: The combination of Pan-ApoE and ApoE4-specific chemiluminescent enzyme immunoassay (CLEIA) assay is useful for predicting APOE ε4 allele status.

Publisher

Open Exploration Publishing

Subject

General Medicine,General Medicine,General Chemistry,Electrical and Electronic Engineering,Atomic and Molecular Physics, and Optics,General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine,General Medicine,General Medicine,General Medicine,General Medicine

Reference29 articles.

1. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.

2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3.

3. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–56.

4. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 2011;10:241–52.

5. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9:197–210.